A Randomized, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses 0.5 mg to 500 mg of BI 409306 Administered Orally in Healthy Male Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses 0.5 mg to 500 mg of BI 409306 Administered Orally in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs BI 409306 (Primary)
  • Indications Affective disorders; Anxiety disorders; Schizophrenia and disorders with psychotic features
  • Focus Adverse reactions; First in man
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2016 Results published in the British Journal of Clinical Pharmacology
    • 23 Aug 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 23 Aug 2011 Trial status changed from recruiting to Completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top